Enovis Corp (ENOV)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $1.60B
Last updated: Nov 17, 2026 at 11:05 AM ET
Enovis Corp (ENOV) Financials: Revenue, Profit and Cash Flow
Enovis reported revenue of $2.25B for the fiscal year ended Dec 31, 2025, up 6.7% from the year before. That year, net income was -$1.18B with a net margin of -52.7%, operating cash flow was $217.29M and free cash flow was $19.92M. The quarter ended Sep 30, 2026 had revenue of $558.73M and net income of $3.42M.
Revenue and Margins
The operating margin was -50.0% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue fell from $3.19B, a compound annual decline of 3.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2.25B | +6.7% | 59.8% | -50.0% | -52.7% |
| Dec 2024 | $2.11B | +23.5% | 56.0% | -36.8% | -39.1% |
| Dec 2023 | $1.71B | +9.2% | 58.0% | -3.8% | -1.9% |
| Dec 2022 | $1.56B | +9.6% | 55.6% | -4.6% | -0.8% |
| Dec 2021 | $1.43B | +27.3% | 54.5% | -4.4% | 5.3% |
| Dec 2020 | $1.12B | -66.3% | 53.9% | -5.9% | 4.1% |
| Dec 2019 | $3.33B | +51.7% | 42.1% | 6.1% | -15.5% |
| Dec 2018 | $2.19B | +13.2% | 33.3% | 6.9% | 7.0% |
| Dec 2017 | $1.94B | -39.2% | 34.7% | 7.0% | 8.7% |
| Dec 2016 | $3.19B | N/A | 31.2% | 7.4% | 4.6% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.25B | $2.11B | $1.71B | $1.56B | $1.43B | $1.12B | $3.33B | $2.19B | $1.94B | $3.19B |
| Cost of revenue | $902.79M | $926.87M | $716.42M | $693.72M | $648.51M | $517.06M | $1.93B | $1.46B | $1.27B | $2.19B |
| Gross profit | $1.35B | $1.18B | $990.78M | $869.38M | $777.67M | $603.64M | $1.40B | $729.38M | $671.58M | $992.38M |
| Research and development | $120.33M | $91.30M | $75.33M | $60.83M | $49.09M | $34.27M | $0 | $0 | $0 | $0 |
| Operating income | -$1.12B | -$775.72M | -$65.71M | -$71.18M | -$62.80M | -$66.18M | $203.61M | $151.54M | $135.60M | $236.85M |
| Net income | -$1.18B | -$824.82M | -$32.73M | -$11.76M | $76.28M | $45.77M | -$517.15M | $154.47M | $169.51M | $145.19M |
| EBITDA | -$830.22M | -$481.03M | $177.06M | $159.42M | $200.12M | $180.05M | $406.02M | $293.45M | $220.87M | $374.02M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $558.73M | $582.78M | $589.15M | $575.76M | $548.91M | $564.54M | $558.83M | $560.98M | $505.22M | $525.16M | $516.27M | $455.02M |
| Gross profit | $339.85M | $359.25M | $365.49M | $349.42M | $328.91M | $334.70M | $332.23M | $307.52M | $286.46M | $288.88M | $297.90M | $264.39M |
| Operating income | $3.38M | $17.41M | $6.53M | -$502.18M | -$558.49M | -$16.80M | -$46.77M | -$664.75M | -$31.74M | -$44.22M | -$35.01M | -$5.75M |
| Net income | $3.42M | -$1.04M | -$8.45M | -$520.45M | -$570.91M | -$36.55M | -$55.70M | -$703.20M | -$31.26M | -$18.51M | -$71.84M | $3.08M |
Balance Sheet
As of Dec 2025, total debt of $1.30B exceeded cash and equivalents by $1.26B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.83B | $4.72B | $4.51B | $4.27B | $8.52B | $7.35B | $7.39B | $6.62B | $6.71B | $6.34B |
| Current assets | $1.21B | $1.15B | $896.52M | $795.02M | $2.30B | $1.36B | $1.40B | $1.96B | $2.07B | $1.74B |
| Cash and equivalents | $36.39M | $48.17M | $36.19M | $24.30M | $680.25M | $97.07M | $109.63M | $77.15M | $262.02M | $208.81M |
| Total liabilities | $2.34B | $2.15B | $1.09B | $823.45M | $3.85B | $3.76B | $3.90B | $3.14B | $2.98B | $3.25B |
| Short-term debt | $35.00M | $20.03M | $0 | $219.28M | $7.70M | $27.07M | $27.64M | $5.02M | $5.77M | $5.41M |
| Long-term debt | $1.26B | $1.31B | $466.16M | $40.00M | $2.08B | $2.20B | $2.28B | $1.19B | $1.06B | $1.29B |
| Shareholder equity | $1.49B | $2.56B | $3.42B | $3.45B | $4.62B | $3.54B | $3.44B | $3.27B | $3.50B | $2.90B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.74B | $3.77B | $3.83B | $3.83B | $4.43B | $5.02B | $4.88B | $4.72B | $5.55B | $5.44B | $5.48B | $4.51B |
| Total liabilities | $2.24B | $2.29B | $2.35B | $2.34B | $2.41B | $2.44B | $2.25B | $2.15B | $2.22B | $2.15B | $2.17B | $1.09B |
| Cash and equivalents | $13.04M | $12.56M | $33.13M | $36.39M | $33.62M | $44.07M | $38.46M | $48.17M | $35.42M | $35.00M | $66.27M | $36.19M |
| Shareholder equity | $1.49B | $1.48B | $1.48B | $1.49B | $2.02B | $2.58B | $2.62B | $2.56B | $3.33B | $3.29B | $3.31B | $3.42B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 9.2% of operating cash flow. Share repurchases came to 17.6% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $217.29M | $113.50M | $134.99M | -$55.86M | $356.10M | $301.94M | $130.95M | $226.37M | $218.77M | $246.97M |
| Capital expenditures | $197.38M | $180.71M | $122.22M | $105.45M | $104.24M | $114.78M | $125.40M | $69.65M | $68.77M | $63.25M |
| Free cash flow | $19.92M | -$67.21M | $12.77M | -$161.31M | $251.86M | $187.15M | $5.55M | $156.72M | $150.00M | $183.72M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | N/A | $93.50M | $0 | $0 | $896.74M |
| Share repurchases | $3.50M | $4.77M | $0 | $0 | N/A | N/A | N/A | $200.00M | $0 | $20.81M |
| Investing cash flow | -$179.37M | -$955.47M | -$242.47M | -$176.39M | -$320.48M | -$175.08M | -$1.63B | -$167.85M | $89.88M | -$81.99M |
| Financing cash flow | -$52.40M | $846.82M | $127.80M | -$465.13M | $584.91M | -$131.65M | $1.37B | -$47.15M | -$280.45M | -$145.22M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $71.49M | $75.03M | $23.95M | $88.54M | $82.58M | $47.77M | -$1.60M | $88.33M | $53.56M | $7.77M | -$36.16M | $68.42M |
| Capital expenditures | $36.51M | $43.90M | $52.80M | $56.25M | $53.49M | $44.37M | $43.26M | $53.19M | $51.19M | $39.41M | $36.93M | $27.94M |
| Free cash flow | $34.99M | $31.14M | -$28.85M | $32.29M | $29.09M | $3.40M | -$44.86M | $35.14M | $2.37M | -$31.63M | -$73.08M | $40.47M |
Frequently Asked Questions About ENOV
What is Enovis' annual revenue?
Enovis reported revenue of $2.25B for the fiscal year ended Dec 31, 2025.
How fast is Enovis' revenue growing?
Revenue was up 6.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 12.9%.
Is Enovis profitable?
No. Enovis reported net income of -$1.18B for the fiscal year ended Dec 31, 2025, with a net margin of -52.7%.
How much free cash flow does ENOV generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $217.29M minus capital expenditures of $197.38M produced free cash flow of $19.92M.
How much debt does Enovis have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $1.26B, short-term debt of $35.00M and cash and equivalents of $36.39M.
ENOV pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors